About a third of people with relapsing-remitting multiple sclerosis (RRMS) exhibit cognitive impairments, according to a review by Australian researchers of 50 previously published studies. The findings suggest that cognitive issues might be somewhat less common in RRMS than previous reports have indicated, with prior estimates ranging from approximately…

Daily treatment with CNM-Au8 led to sustained improvements in vision and cognition for people with relapsing-remitting multiple sclerosis (RRMS), according to nearly three years of follow-up in the VISIONARY-MS trial and its open-label extension (OLE). Developer Clene Nanomedicine plans to present full trial results at the upcoming ACTRIMS…

Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were associated with the enlargement of brain lesions and of fluid-filled brain cavities called ventricles in people with relapsing-remitting MS (RRMS) undergoing Tysabri (natalizumab) treatment, a study showed. While…

Following a ketogenic diet — one that’s low in carbohydrates and rich in fat — for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study showed.

People with relapsing-remitting multiple sclerosis (RRMS) who are receiving oral disease-modifying therapies (DMTs) are still more likely to experience a relapse or any form of disease activity if they are smokers, a study found. Researchers also observed that former smokers had a disease…

Researchers in Iran are conducting a clinical trial to test the effects of taking ginger supplements for people with relapsing-remitting multiple sclerosis (RRMS). Ginger extracts have shown some promise in animal models of multiple sclerosis (MS), but no trial has yet determined the impact that ginger supplements may…

Delaying the start of disease-modifying therapies (DMTs) increases the risk of people with relapsing-remitting multiple sclerosis (RRMS) needing a disability pension to compensate for a permanent reduced capacity to work,  according to a Danish study. The study, “Time to first treatment and risk of disability pension…

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…

Connectivity between parts of the brain related to vision and attention is altered in people with relapsing-remitting multiple sclerosis (RRMS), both during rest and while actively engaged in a task, a new study indicates. The study, “Altered brain network function during attention-modulated visual processing in multiple…